View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 14, 2022

Sanofi’s oral SERD fails to meet primary endpoint in Phase II breast cancer trial

The open-label, randomised trial assessed the safety and the efficacy of amcenestrant versus endocrine therapy.

Sanofi has reported that its Phase II AMEERA-3 clinical trial of investigational oral therapy, amcenestrant, in breast cancer patients failed to meet the primary endpoint of boosting progression-free survival (PFS). 

An optimised oral selective estrogen receptor degrader (SERD), amcenestrant attaches to the estrogen receptors (ER) in breast cancer cells. 

It thereby hinders the normal function and induces degradation of ERs, due to which they can no longer be used for the growth of tumour cells.

The open-label, randomised trial is designed to assess the safety and the efficacy of amcenestrant as a monotherapy versus single-agent endocrine therapy chosen by the physician.

It enrolled subjects with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancers (MBC) and have advanced on or following treatment with hormonal therapies. 

Analysing if amcenestrant boosted PFS as evaluated by an independent central review compared to endocrine monotherapy was the trial’s primary objective.

Overall survival was the crucial secondary efficacy endpoint while disease control rate, objective response rate, duration of response and clinical benefit rate were included as other secondary endpoints of the trial

Furthermore, the trial compared the overall safety profile in the two treatment arms and assessed the health-associated quality of life in these arms based on outcomes reported by the subjects.

No new safety signals were reported and amcenestrant’s safety profile in the AMEERA-3 trial was in line with prior studies, Sanofi noted.

The ongoing clinical trial programme of amcenestrant, including AMEERA-5 and AMEERA-6, will progress as scheduled.

Sanofi Research and Development head John Reed said: “This Phase II trial evaluated amcenestrant as a monotherapy in a patient population with advanced disease where limited treatment options remain. 

“While we are disappointed with the AMEERA-3 results, we continue to investigate amcenestrant in patients with earlier stages of breast cancer with different tumour profiles and where different standard of care treatments are used.”

In December last year, the company reported that its Dupixent (dupilumab) antibody substantially boosted skin clearance in the Phase III trial in children.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy